Thursday, December 27, 2018 10:02:40 AM
But it's interesting to note that "Eich's" concern does assume efficacy and approval for our therapies. I made the point that it's not impossible to ramp up production (as 999 cleverly noticed, it's NOT 20K per bioreactor run), but sheer physical buildout of bioreactors may produce enough initially. Let's remember, a quick acceptance of PLX in the medical community is a good thing, having to ramp up production is a good thing, it means a massive influx of funds (20,000 doses X $30K per dose, or however the pricing is done, and your's getting close to half a billion dollars).
I'm looking forward to the problem/challenge of trying to meet a tremendous demand for our drugs!
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM